Jazz Pharmaceuticals plc (NASDAQ:JAZZ) Shares Sold by Point72 Asia Singapore Pte. Ltd.

Point72 Asia Singapore Pte. Ltd. lowered its position in shares of Jazz Pharmaceuticals plc (NASDAQ:JAZZ - Free Report) by 85.5% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 2,117 shares of the specialty pharmaceutical company's stock after selling 12,476 shares during the period. Point72 Asia Singapore Pte. Ltd.'s holdings in Jazz Pharmaceuticals were worth $261,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also made changes to their positions in the company. Barclays PLC grew its holdings in shares of Jazz Pharmaceuticals by 19.1% during the third quarter. Barclays PLC now owns 39,210 shares of the specialty pharmaceutical company's stock worth $4,369,000 after buying an additional 6,289 shares during the last quarter. Park Avenue Securities LLC grew its holdings in shares of Jazz Pharmaceuticals by 19.5% during the fourth quarter. Park Avenue Securities LLC now owns 2,521 shares of the specialty pharmaceutical company's stock worth $310,000 after buying an additional 412 shares during the last quarter. Empirical Asset Management LLC purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth about $5,359,000. Arkadios Wealth Advisors purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth about $716,000. Finally, Kera Capital Partners Inc. purchased a new position in shares of Jazz Pharmaceuticals during the fourth quarter worth about $288,000. Institutional investors and hedge funds own 89.14% of the company's stock.

Jazz Pharmaceuticals Price Performance

Shares of NASDAQ:JAZZ traded up $1.24 during trading on Tuesday, hitting $111.02. 1,230,970 shares of the stock were exchanged, compared to its average volume of 849,129. The company has a fifty day moving average price of $114.74 and a two-hundred day moving average price of $122.01. The company has a market cap of $6.84 billion, a PE ratio of 15.64, a P/E/G ratio of 1.04 and a beta of 0.38. The company has a current ratio of 4.26, a quick ratio of 3.74 and a debt-to-equity ratio of 1.46. Jazz Pharmaceuticals plc has a 12-month low of $95.49 and a 12-month high of $148.06.

Jazz Pharmaceuticals (NASDAQ:JAZZ - Get Free Report) last issued its quarterly earnings data on Tuesday, May 6th. The specialty pharmaceutical company reported $1.68 earnings per share (EPS) for the quarter, missing the consensus estimate of $4.65 by ($2.97). Jazz Pharmaceuticals had a return on equity of 29.30% and a net margin of 11.60%. The company had revenue of $897.84 million for the quarter, compared to analyst estimates of $984.16 million. During the same quarter in the prior year, the firm earned $2.68 earnings per share. The company's revenue for the quarter was down .5% on a year-over-year basis. On average, analysts forecast that Jazz Pharmaceuticals plc will post 16.96 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on JAZZ. Royal Bank of Canada lowered their price target on Jazz Pharmaceuticals from $182.00 to $172.00 and set an "outperform" rating on the stock in a report on Wednesday, May 7th. Barclays reaffirmed an "overweight" rating and issued a $200.00 price objective (up previously from $190.00) on shares of Jazz Pharmaceuticals in a report on Thursday, February 27th. Cantor Fitzgerald lowered Jazz Pharmaceuticals from an "overweight" rating to a "neutral" rating and lifted their price objective for the company from $140.00 to $150.00 in a report on Wednesday, February 26th. Wells Fargo & Company raised Jazz Pharmaceuticals from an "equal weight" rating to an "overweight" rating and lifted their price objective for the company from $130.00 to $170.00 in a report on Thursday, February 13th. Finally, StockNews.com lowered Jazz Pharmaceuticals from a "buy" rating to a "hold" rating in a report on Thursday, May 15th. Two investment analysts have rated the stock with a hold rating and thirteen have given a buy rating to the company's stock. According to MarketBeat.com, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $182.79.

Insider Buying and Selling

In related news, CEO Bruce C. Cozadd sold 6,500 shares of Jazz Pharmaceuticals stock in a transaction that occurred on Monday, March 3rd. The stock was sold at an average price of $144.25, for a total transaction of $937,625.00. Following the completion of the transaction, the chief executive officer now directly owns 464,058 shares in the company, valued at $66,940,366.50. The trade was a 1.38% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, CAO Patricia Carr sold 4,813 shares of the business's stock in a transaction on Thursday, February 27th. The shares were sold at an average price of $144.42, for a total value of $695,093.46. Following the completion of the transaction, the chief accounting officer now owns 8,237 shares of the company's stock, valued at $1,189,587.54. This trade represents a 36.88% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 28,236 shares of company stock worth $3,956,190 in the last ninety days. Insiders own 4.20% of the company's stock.

Jazz Pharmaceuticals Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.